Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isao Asakawa

Showing results (11-20 of 64) with videos related to

Pageof 7
Sort By:
Radiation Oncology (London, England)|February 1, 2013
Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapyNobumichi Tanaka, Isao Asakawa, Satoshi Anai, et al.
BMC Urology|September 15, 2012
Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancerNobumichi Tanaka, Isao Asakawa, Kiyohide Fujimoto, et al.
The Prostate|May 12, 2024
Efficacy of a hydrogel spacer for improving quality of life in patients with prostate cancer undergoing low-dose-rate brachytherapy alone or in combination with intensity-modulated radiotherapy: An observational study using propensity score matchingYasushi Nakai, Nobumichi Tanaka, Isao Asakawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 17, 2009
[Application of PET in radiation oncology]Masatoshi Hasegawa, Fumiaki Uto, Isao Asakawa, et al.
BMC Research Notes|October 27, 2014
Salvage brachytherapy for seminal vesicle recurrence after initial brachytherapy for prostate cancer: a case reportShunta Hori, Nobumichi Tanaka, Isao Asakawa, et al.
The Prostate|January 22, 2026
Effect of Celecoxib Combined With Low-Dose-Rate Brachytherapy on Long-Term Oncological Outcomes and Quality of Life in Prostate Cancer: Post Hoc Analysis of an Open-Label Controlled Randomized TrialYasushi Nakai, Kenta Onishi, Isao Asakawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|January 6, 2009
Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patientsNobumichi Tanaka, Isao Asakawa, Hideaki Kondo, et al.
Andrologia|October 25, 2021
Erectile dysfunction and sexual quality of life in patients who underwent low-dose-rate brachytherapy alone for prostate cancerYasushi Nakai, Nobumichi Tanaka, Isao Asakawa, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 8, 2024
Effectiveness of intraoral stents in reducing oral adverse events during radiotherapy for maxillary or nasal cavity malignant tumorsMao Kawakami, Nobuhiro Ueda, Kaori Yamaki, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 20, 2022
Local dose (biologically effective dose ≥180 Gy2) is an important predictor of biochemical recurrence in patients undergoing low-dose-rate brachytherapyNobumichi Tanaka, Yasushi Nakai, Isao Asakawa, et al.
Pageof 7

Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
Radiation Oncology (London, England)|February 1, 2013
Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapyNobumichi Tanaka, Isao Asakawa, Satoshi Anai, et al.
BMC Urology|September 15, 2012
Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancerNobumichi Tanaka, Isao Asakawa, Kiyohide Fujimoto, et al.
The Prostate|May 12, 2024
Efficacy of a hydrogel spacer for improving quality of life in patients with prostate cancer undergoing low-dose-rate brachytherapy alone or in combination with intensity-modulated radiotherapy: An observational study using propensity score matchingYasushi Nakai, Nobumichi Tanaka, Isao Asakawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 17, 2009
[Application of PET in radiation oncology]Masatoshi Hasegawa, Fumiaki Uto, Isao Asakawa, et al.
BMC Research Notes|October 27, 2014
Salvage brachytherapy for seminal vesicle recurrence after initial brachytherapy for prostate cancer: a case reportShunta Hori, Nobumichi Tanaka, Isao Asakawa, et al.
The Prostate|January 22, 2026
Effect of Celecoxib Combined With Low-Dose-Rate Brachytherapy on Long-Term Oncological Outcomes and Quality of Life in Prostate Cancer: Post Hoc Analysis of an Open-Label Controlled Randomized TrialYasushi Nakai, Kenta Onishi, Isao Asakawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|January 6, 2009
Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patientsNobumichi Tanaka, Isao Asakawa, Hideaki Kondo, et al.
Andrologia|October 25, 2021
Erectile dysfunction and sexual quality of life in patients who underwent low-dose-rate brachytherapy alone for prostate cancerYasushi Nakai, Nobumichi Tanaka, Isao Asakawa, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 8, 2024
Effectiveness of intraoral stents in reducing oral adverse events during radiotherapy for maxillary or nasal cavity malignant tumorsMao Kawakami, Nobuhiro Ueda, Kaori Yamaki, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 20, 2022
Local dose (biologically effective dose ≥180 Gy2) is an important predictor of biochemical recurrence in patients undergoing low-dose-rate brachytherapyNobumichi Tanaka, Yasushi Nakai, Isao Asakawa, et al.
Pageof 7